ImmuCell Corp. (ICCC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1155880,
    "name": "ImmuCell Corp.",
    "stock_name": "ImmuCell Corp.",
    "full_name": "ImmuCell Corp.",
    "name_url": "stocks-analysis/immucell-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "5.21",
    "chg": 0.21,
    "chgp": "4.2%",
    "dir": 1,
    "prev_price": "5.00",
    "mcapval": "59.71",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US4525253062",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "22.41 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/immucell-corp-1155880-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ImmuCell Corp. Experiences Valuation Adjustment Amidst Strong Yearly Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/immucell-corp-sees-valuation-grade-shift-from-attractive-to-expensive-amid-price-decline-3686211",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ImmuCellCorp_valuationdot_3686211.png",
        "date": "2025-11-10 15:41:35",
        "description": "ImmuCell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, currently priced at $6.10. Over the past year, it achieved a 72.80% return, significantly outperforming the S&P 500. However, the company remains loss-making, with negative returns on capital and equity."
      },
      {
        "title": "Is ImmuCell Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immucell-corp-overvalued-or-undervalued-3637346",
        "imagepath": "",
        "date": "2025-10-21 12:00:29",
        "description": "As of 17 October 2025, the valuation grade for ImmuCell Corp. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 2.05 and an EV to EBITDA ratio of 26.30, which are significantly higher than typical industry benchmarks. Additionally, the company has a negative ROCE of -0.63% and ROE of -0.94%, suggesting inefficiencies in generating returns.\n\nIn comparison to its peers, ImmuCell Corp. has a notably high P/E ratio of 33.88, while ImmunoPrecise Antibodies Ltd. shows a negative P/E of -13.04, and Rani Therapeutics Holdings, Inc. also reflects a negative P/E of -0.74, indicating that ImmuCell is trading at a premium despite its losses. Over the past year, ImmuCell has outperformed the S&P 500 with a return of 67.17% compared to the index's 14.08%, but its long-term performa..."
      },
      {
        "title": "ImmuCell Corp. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/immucell-corp-sees-valuation-grade-shift-from-attractive-to-expensive-amid-losses-3640725",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ImmuCellCorp_valuationdot_3640725.png",
        "date": "2025-10-20 16:16:27",
        "description": "ImmuCell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, faces challenges with a negative P/E ratio and a Price to Book Value of 2.05. Despite a strong one-year return of 67.17%, its three-year performance shows volatility, contrasting with broader market trends and peer valuations."
      },
      {
        "title": "Is ImmuCell Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immucell-corp-overvalued-or-undervalued-3631756",
        "imagepath": "",
        "date": "2025-10-19 11:56:01",
        "description": "As of 17 October 2025, the valuation grade for ImmuCell Corp. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued, particularly given its negative P/E ratio and low ROCE of -0.63%. Key ratios include a Price to Book Value of 2.05, an EV to EBITDA of 26.30, and an EV to Sales of 2.39, which suggest that the company is trading at a premium relative to its earnings and sales potential.\n\nIn comparison to its peers, ImmuCell Corp. has a significantly higher P/E ratio of 33.88, while its closest competitors, such as ImmunoPrecise Antibodies Ltd. and Rani Therapeutics Holdings, Inc., report negative P/E ratios, indicating they are also struggling financially. Over the past year, ImmuCell Corp. has outperformed the S&P 500 with a return of 67.17% compared to the index's 14.08%, but this strong performance may not be sustainable given its current val..."
      },
      {
        "title": "Is ImmuCell Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immucell-corp-technically-bullish-or-bearish-3544771",
        "imagepath": "",
        "date": "2025-09-20 18:55:46",
        "description": "As of 4 September 2025, the technical trend for ImmuCell Corp. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The daily moving averages are mildly bullish, suggesting some short-term support. However, the weekly Bollinger Bands are bearish, which adds to the caution. The stock has underperformed the S&P 500 over the past week and month, with returns of -7.67% and -7.36% respectively, while it has outperformed over the past year with a return of 57.22% compared to the S&P 500's 17.14%. Overall, the current stance is mildly bullish, but with significant caution due to mixed indicators...."
      },
      {
        "title": "Is ImmuCell Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immucell-corp-overvalued-or-undervalued-3541502",
        "imagepath": "",
        "date": "2025-09-20 17:27:43",
        "description": "As of 14 August 2025, the valuation grade for ImmuCell Corp. has moved from risky to expensive, indicating a shift towards a more negative outlook. The company appears to be overvalued, particularly given its P/B ratio of 2.05 and an EV to EBITDA ratio of 26.30, which suggest that the stock is trading at a premium compared to its earnings potential. Additionally, the negative ROCE of -0.63% and ROE of -0.94% further reinforce concerns about the company's profitability.\n\nIn comparison to its peers, ImmuCell Corp. has a significantly higher P/E ratio of 33.88, while ImmunoPrecise Antibodies Ltd. shows a negative P/E of -13.04, indicating that ImmuCell is priced much higher despite its losses. Rani Therapeutics Holdings, Inc. and HOOKIPA Pharma, Inc. also reflect a risky valuation status, highlighting the challenges within this sector. Over the past year, ImmuCell has outperformed the S&P 500 with a return of ..."
      }
    ],
    "total": 11,
    "sid": "1155880",
    "stock_news_url": "https://www.marketsmojo.com/news/immucell-corp-1155880"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

ImmuCell Corp. Experiences Valuation Adjustment Amidst Strong Yearly Performance Metrics

2025-11-10 15:41:35

ImmuCell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, currently priced at $6.10. Over the past year, it achieved a 72.80% return, significantly outperforming the S&P 500. However, the company remains loss-making, with negative returns on capital and equity.

Is ImmuCell Corp. overvalued or undervalued?

2025-10-21 12:00:29

As of 17 October 2025, the valuation grade for ImmuCell Corp. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 2.05 and an EV to EBITDA ratio of 26.30, which are significantly higher than typical industry benchmarks. Additionally, the company has a negative ROCE of -0.63% and ROE of -0.94%, suggesting inefficiencies in generating returns. In comparison to its peers, ImmuCell Corp. has a notably high P/E ratio of 33.88, while ImmunoPrecise Antibodies Ltd. shows a negative P/E of -13.04, and Rani Therapeutics Holdings, Inc. also reflects a negative P/E of -0.74, indicating that ImmuCell is trading at a premium despite its losses. Over the past year, ImmuCell has outperformed the S&P 500 with a return of 67.17% compared to the index's 14.08%, but its long-term performa...

ImmuCell Corp. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics

2025-10-20 16:16:27

ImmuCell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, faces challenges with a negative P/E ratio and a Price to Book Value of 2.05. Despite a strong one-year return of 67.17%, its three-year performance shows volatility, contrasting with broader market trends and peer valuations.

Is ImmuCell Corp. overvalued or undervalued?

2025-10-19 11:56:01

As of 17 October 2025, the valuation grade for ImmuCell Corp. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued, particularly given its negative P/E ratio and low ROCE of -0.63%. Key ratios include a Price to Book Value of 2.05, an EV to EBITDA of 26.30, and an EV to Sales of 2.39, which suggest that the company is trading at a premium relative to its earnings and sales potential. In comparison to its peers, ImmuCell Corp. has a significantly higher P/E ratio of 33.88, while its closest competitors, such as ImmunoPrecise Antibodies Ltd. and Rani Therapeutics Holdings, Inc., report negative P/E ratios, indicating they are also struggling financially. Over the past year, ImmuCell Corp. has outperformed the S&P 500 with a return of 67.17% compared to the index's 14.08%, but this strong performance may not be sustainable given its current val...

Is ImmuCell Corp. technically bullish or bearish?

2025-09-20 18:55:46

As of 4 September 2025, the technical trend for ImmuCell Corp. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The daily moving averages are mildly bullish, suggesting some short-term support. However, the weekly Bollinger Bands are bearish, which adds to the caution. The stock has underperformed the S&P 500 over the past week and month, with returns of -7.67% and -7.36% respectively, while it has outperformed over the past year with a return of 57.22% compared to the S&P 500's 17.14%. Overall, the current stance is mildly bullish, but with significant caution due to mixed indicators....

Is ImmuCell Corp. overvalued or undervalued?

2025-09-20 17:27:43

As of 14 August 2025, the valuation grade for ImmuCell Corp. has moved from risky to expensive, indicating a shift towards a more negative outlook. The company appears to be overvalued, particularly given its P/B ratio of 2.05 and an EV to EBITDA ratio of 26.30, which suggest that the stock is trading at a premium compared to its earnings potential. Additionally, the negative ROCE of -0.63% and ROE of -0.94% further reinforce concerns about the company's profitability. In comparison to its peers, ImmuCell Corp. has a significantly higher P/E ratio of 33.88, while ImmunoPrecise Antibodies Ltd. shows a negative P/E of -13.04, indicating that ImmuCell is priced much higher despite its losses. Rani Therapeutics Holdings, Inc. and HOOKIPA Pharma, Inc. also reflect a risky valuation status, highlighting the challenges within this sector. Over the past year, ImmuCell has outperformed the S&P 500 with a return of ...

View All News